PDA vs VIP
Both PDA and VIP are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
PDA
Evidence C+Pentadeca Arginate (PDA)
A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.
View full PDA profile →VIP
Evidence BVasoactive Intestinal Peptide
A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
View full VIP profile →Side-by-Side
| Attribute | PDA | VIP |
|---|---|---|
| Evidence Grade | C+ | B |
| FDA Status | Not FDA-approved — newer compounded analog of BPC-157 | Not FDA-approved — investigational; ongoing trials for sarcoidosis |
| Typical Dose | 200–500 mcg daily (subcutaneous) | 50 mcg intranasal, 4 times daily (CIRS protocols) |
| Clinics Indexed | 41 | 24 |
| Categories | recovery, anti-inflammatory | anti-inflammatory, neuroprotection |
Key reported benefits — PDA
- ✓Tissue repair
- ✓Anti-inflammation
- ✓Potentially better stability than BPC-157
Key reported benefits — VIP
- ✓Anti-inflammation
- ✓Pulmonary effects
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.